FRESENIUS MEDICAL CARE - FINANCIAL FIGURES 2022
WHO WE ARE
Creating a future worth living. For our patients. Worldwide. Every day.
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. United by a shared purpose of creating a future worth living for chronically and critically ill patients, we care for more than 344,000 dialysis patients around the globe. Their well-being always comes first.
It is our mission to provide the best possible care for a growing number of patients sustainably in diverse health care systems. As a vertically integrated company, our portfolio encompasses a comprehensive range of high-quality health care products and services as well as various dialysis treatment options for both in-center and home dialysis.
patients
worldwide
More than
dialysis treatments
in 2022
of our patients
would highly recommend
our services
dialysis centers
in around
50 countries
of dialysis treatments
in the U.S.
performed in-center
of dialysis treatments
in the U.S.
performed at home
production
sites
Products
in around
countries
We are the
market leader
in the production of
hemodialysis machines
Around
dialyzers produced
in 2022
More than
diverse suppliers
in the U.S.
market share in
Continuous Renal
Replacement Therapy
ethnically
diverse workforce
in the U.S.
Revenue
Continued organic growth
HEALTH CARE SERVICES
HEALTH CARE PRODUCTS
NORTH AMERICA
EUROPE, MIDDLE EAST AND AFRICA
ASIA-PACIFIC
LATIN AMERICA
Operating
Income
Operating income impacted by
labor and cost inflation
1At constant currency
2Special items will be provided as separate KPI to capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. These items are excluded to ensure comparability of the figures presented with the Company’s financial targets which have been defined excluding special items. For FY 2022, special items included costs related to the FME25 program, the impact of the war in Ukraine, the impact of hyperinflation in Turkiye, the remeasurement effect on the fair value of the investment in Humacyte, Inc., and the net gain related to InterWell Health.
Net
Income
Results in line with expectations
1At constant currency
2Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA.
3Special items will be provided as separate KPI to capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. These items are excluded to ensure comparability of the figures presented with the Company’s financial targets which have been defined excluding special items. For FY 2022, special items included costs related to the FME25 program, the impact of the war in Ukraine, the impact of hyperinflation in Turkiye, the remeasurement effect on the fair value of the investment in Humacyte, Inc., and the net gain related to InterWell Health.
Dividend
Proposal for dividend payment planned
1Planned proposal to be approved by the Annual General Meeting on May 16, 2023.